AlphaMaven AlphaMaven

New Innovation Quotient Framework Brings Structured Evidence to Venture Capital Evaluations

Reported by Bioengineer
Nov 9, 2026· 3 min read
Save Post LinkedIn Email
Key Takeaways
  • • Researchers Mahdi Khobreh, Ehsan Chitsaz, and Mohammad Reza Heidarzadeh have proposed the Venture-Ready Innovation Quotient, a structured diagnostic framework for early-stage venture capital due diligence, as reported by Bioengineer.org.
  • • The framework scores startups across three dimensions (Potential, Execution, and Impact) on a 1-to-5 scale across nine sub-dimensions, replacing linear checklists and single-score composite metrics.
  • • A proposed Outlier Potential Index (Impact multiplied by the greater of Potential or Execution) is designed to reflect power-law return dynamics in venture capital.
  • • A pilot validation study of 35 accelerator-backed ventures reported an inter-rater ICC(2,k) of 0.85, but the authors state the two-rater, single-accelerator sample is a proof-of-concept requiring broader replication.
  • • The model is theoretical and hypothetical in its applied examples; it has not been validated at institutional scale.
Summary
Researchers Mahdi Khobreh, Ehsan Chitsaz, and Mohammad Reza Heidarzadeh have formulated the Venture-Ready Innovation Quotient, a structured diagnostic framework intended to bridge academic management theory and early-stage venture capital due diligence, according to Bioengineer.org. The model departs from linear checklists and single-score composite metrics by producing a multidimensional profile across three dimensions: Potential, Execution, and Impact. The framework draws on the resource-based view, dynamic capabilities theory, signaling theory, and agency theory, and uses a behaviorally anchored scoring rubric to convert qualitative venture attributes into evidence-based ratings.

The authors position the framework as a response to the difficulty of valuing pre-revenue companies, where discounted cash flow methods are often unsuitable and investors rely heavily on heuristics. The paper cites documented cognitive distortions in venture decision-making, including gender disparities in capital allocation, attractiveness bias, and overconfidence, and notes that existing algorithmic tools struggle with qualitative factors such as founder quality and technological defensibility. The framework is presented as a quantitative foundation for algorithmic screening, portfolio optimization, and investment committee reviews.

Each dimension is scored through nine sub-dimensions across a five-stage innovation funnel, from Idea and Team through Scalable Impact. Ratings run from one to five against observable milestones. Dimension scores are arithmetic means of their sub-dimensions, and an overall composite is a weighted sum using investor-defined weights. The authors suggest weights can be set through the Analytic Hierarchy Process, Best-Worst Method, regression on historical outcomes, or partner consensus, and report rank-order correlations above 0.95 between arithmetic and geometric mean aggregation. The Outlier Potential Index, defined as Impact multiplied by the greater of Potential or Execution, is intended to capture non-linear upside. The authors link deal structuring to archetypes: science projects with high potential but low execution may warrant milestone-based tranches and tight board control, while execution-led ventures with limited market ceilings may warrant anti-dilution protections.

In illustrative hypothetical cases, ConnectSphere, a two-year-old freelancer marketplace, scored high on execution with 47% month-over-month gross merchandise volume growth and a Net Promoter Score of 52, but a low intellectual property score of two. Under a Series A weighting of 0.5 execution, 0.3 impact, and 0.2 potential, it achieved a composite of approximately 3.77. QuantumLeap AI, a deep-tech university spin-off, scored five in intellectual property and product innovation but one in market traction.

Preliminary psychometric evidence comes from a pilot study of 35 early-stage ventures in a university-affiliated accelerator, scored by two trained evaluators. The inter-rater ICC(2,k) was 0.85 (95% CI 0.77 to 0.91), and Cronbach's alpha was 0.82 for Potential, 0.79 for Execution, and 0.85 for Impact. The authors caution that the sample was small, demographically homogeneous, and drawn from a single accelerator, and that multi-rater replication across industries and geographies is needed before the instrument can be considered fully validated. The authors also outline strategies for institutional adoption and for integrating environmental, social, and governance considerations.

Go deeper than the headline

Research every firm in this story, track the ones that matter and get the daily briefing — free for 7 days.

Start your free 7-day trial

Sources

1 outlet

AlphaMaven summarised this story from the reporting below. Each link opens the original article.

Bioengineer New Innovation Quotient Framework Brings Structured Evidence to Venture Capital Evaluations